News
Featured News
Flexibility, creativity, and dedication to make better therapeutics are at the heart of what we do. Read more on recent updates and highlights around our contract drug manufacturing activities.
Agilent Completes Acquisition of BIOVECTRA
September 20, 2024
Agilent Completes Acquisition of BIOVECTRA
Pharmaceutical customers will benefit from a broader set of specialized CDMO capabilities SANTA CLARA, California, September 20, 2024 – Agilent Technologies Inc. (NYSE: A) […]
Agilent Technologies to Acquire BIOVECTRA Inc., Creating New Synergistic Opportunities to Improve Patient Care
CHARLOTTETOWN, Prince Edward Island and SANTA CLARA, California – July 22, 2024 BIOVECTRA Inc. and Agilent Technologies, Inc. (NYSE: A) today announced the signing of […]
BIOVECTRA partners on Canadian solution to establish a domestic supply chain for immunotherapies
BIOVECTRA is pleased to be part of a Canadian solution with our NGEN partners CCRM, Precision Nanosytems (Cytiva), Northern RNA, and OmniaBio to establish […]
BIOVECTRA Launches Specialized Capabilities in mRNA Drug Product Development and Biomanufacturing
CHARLOTTETOWN, PRINCE EDWARD ISLAND, November 17th, 2023 – Today BIOVECTRA celebrates the completion of its $90 million plus biologics expansion at the company’s new state-of-the-art Biomanufacturing […]
BIOVECTRA Signs Service Agreement with Acuitas Therapeutics for Unique Lipid Nanoparticle (LNP) Delivery System Used in Manufacturing mRNA-Based Therapies
CHARLOTTETOWN, Prince Edward Island and VANCOUVER, British Columbia, October 5, 2023 – BIOVECTRA and Acuitas Therapeutics, Inc. today announced that they have entered into a […]
BIOVECTRA Welcomes Normand Blais to Senior Director, Development & Innovation, Biologics Role
Charlottetown, P.E.I. (January 18, 2023) – BIOVECTRA is pleased to announce that Normand Blais was appointed as Senior Director, Development & Innovation, Biologics. Reporting […]
